Moderna Anticipates Increased Revenue Projections for 2025

January 12, 2026 - 21:38

In a recent presentation at the 44th Annual J.P. Morgan Healthcare Conference, Moderna revealed its expectations for 2025 revenue, projecting approximately $1.9 billion (unaudited). This figure represents an increase of $100 million above the midpoint previously communicated during the third quarter of 2025.

The company emphasized its commitment to advancing its innovative pipeline, which includes a range of mRNA-based therapeutics and vaccines. Moderna's leadership highlighted significant progress in clinical trials and ongoing collaborations that are expected to enhance its market position.

As the biotechnology sector continues to evolve, Moderna remains focused on addressing unmet medical needs and expanding its portfolio. The anticipated revenue growth underscores the company's strategic initiatives and the potential impact of its products on public health. Investors and stakeholders are keenly watching how these developments will unfold in the coming years as Moderna aims to solidify its role as a leader in the biopharmaceutical industry.